Article

NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of-Function Mice, and Wild-Type Mice and Rats

2021-08-31

Abstract excerpt

NBI-921352 (formerly XEN901) is a novel sodium channel inhibitor designed to specifically target Na V 1.6 channels. Such a molecule provides a precision-medicine approach to target SCN8A -related epilepsy syndromes ( SCN8A -RES), where gain-of-function (GoF) mutations lead to excess Na V 1.6 sodium current, or other indications where Na V 1.6 mediated hyper-excitability contributes to disease (Gardella and Mo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 371b3ba5-b670-56b8-82f4-6673bfa75045
DOI: 10.1101/2021.08.29.458125

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

NBI-921352, a First-in-Class, Na V 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in Scn8a Gain-of-Function Mice, and Wild-Type Mice and RatsDOI 10.1101/2021.08.29.458125Read

NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.Semantic proximity Read

Na V 1.6 inhibition drives the efficacy of voltage-gated sodium channel inhibitors to prevent electrically induced seizures in both wild type and Scn8a N1768D/+ gain-of-function miceSemantic proximity Read

Differential effects of sodium channel blockers on SCN8A gain-of-function variants associated with drug-responsive or -resistant epilepsySemantic proximity Read

In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders.Semantic proximity Read

In vitro effects of S-Licarbazepine as a potential precision therapy on SCN8A variants causing neuropsychiatric disordersSemantic proximity Read

Gene therapies alleviate absence epilepsy associated with Scn2a deficiency in DBA/2J miceSemantic proximity Read

Recent advances in treatment of epilepsy-related sodium channelopathiesSemantic proximity Read

Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants.Semantic proximity Read

A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.Semantic proximity Read

The novel sodium channel modulator GS-458967 (GS967) is an effective treatment in a mouse model of SCN8A encephalopathy.Semantic proximity Read

Exogenous Na V 1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with DravetSemantic proximity Read

How do mutant Nav1.1 sodium channels cause epilepsy?Semantic proximity Read

NBI-921352, a First-in-Class, Na <sub>V</sub> 1.6 Selective, Sodium Channel Inhibitor That Prevents Seizures in <i>Scn8a</i> Gain-of-Function Mice, and Wild-Type Mice and Rats

Abstract excerpt

Topics

Identifiers and source

Related research